Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Semaglutide reduces appetite by directly activating GLP-1 receptors in brain regions that control hunger and satiety, independently of leptin pathways
Retatrutide is an investigational triple incretin receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
clinicians should monitor for gastrointestinal cramping or bradycardia in co-treated patients
Consider coeliac disease screening if iron deficiency is present or symptoms suggest malabsorption
US$ 26.27
US$ 29.20
,aspect=fit)
US$ 20.98
US$ 27.12
US$ 21.38
US$ 29.80
